UK – NICE clears Opdivo for resected oesophageal or gastro-oesophageal junction cancer

The UK National Institute for Health and Care Excellence (NICE) has recommended Bristol Myers Squibb’s (BMS) Opdivo (nivolumab) as a treatment option for certain resected oesophageal or gastro-oesophageal junction (GEJ) patients.

Opdivo has been cleared as an adjuvant treatment of completely resected oesophageal or GEJ cancer in adults who have residual disease following neoadjuvant chemoradiotherapy.

The recommendation was made based on clinical trial evidence showing that, for people who had residual disease after chemoradiotherapy and following surgery, Opdivo increases the time individuals’ live without their cancer returning compared to placebo…